Benjamin LinderData Scientist at Boehringer Ingelheim
Dr. Lindner thrives the implementation of Next Generation Sequencing (NGS) technology into cell line characterization. Trained as a biochemist, he gained over 10 years’ experience of next and third generation sequencing technologies. Over 5 years he spent developing NGS applications including DNA-seq, RNA-seq and bisulfite-seq at GATC Biotech, Europe’s leading sequencing service provider at that time. Since 2017 he developed pooled CRISPR screens and single cell RNA-seq to identify regulators of phagocytosis at Boehringer Ingelheim. More recently, he implemented RNA-seq for sequence variant detection in early-stage development of CHO cell line generation.